ADAM17 is understood to be involved in the processing of tumor necrosis factor alpha (TNF-α) at the surface of the cell, and from within the intracellular membranes of the trans-Golgi network. This process, which is also known as 'shedding', involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-α), and is of known physiological importance. ADAM17 was the first 'sheddase' to be identified, and is also understood to play a role in the release of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands, and enzymes.
Cloning of the TNF-α gene revealed it to encode a 26 kDa type II transmembrane pro-polypeptide that becomes inserted into the cell membrane during its maturation. At the cell surface, pro-TNF-α is biologically active, and is able to induce immune responses via juxtacrine intercellular signaling. However, pro-TNF-α can undergo a proteolytic cleavage at its Ala76-Val77 amide bond, which releases a soluble 17kDa extracellular domain (ectodomain) from the pro-TNF-α molecule. This soluble ectodomain is the cytokine commonly known as TNF-α, which is of pivotal importance in paracrine signaling. This proteolytic liberation of soluble TNF-α is catalyzed by ADAM17.
Recent in vitro experiments have provided evidence that suggests that ADAM17 may play a prominent role in the Notch signaling pathway, during the proteolytic release of the Notch intracellular domain (from the Notch1 receptor) that occurs following ligand binding. ADAM17 also regulates the MAP kinase signaling pathway by regulating shedding of the EGFR ligand amphiregulin in the mammary gland.
The localization of ADAM17 is speculated to be an important determinant of shedding activity. TNF-α processing has classically been understood to occur in the trans-Golgi network, and be closely connected to transport of soluble TNF-α to the cell surface. However, research that suggests that the majority of mature, endogenous ADAM17 may be localized to a perinuclear compartment, with only a small amount of TACE being present on the cell surface. The localization of mature ADAM17 to a perinuclear compartment, therefore, raises the possibility that ADAM17-mediated ectodomain shedding may also occur in the intracellular environment, in contrast with the conventional model.
Functional ADAM17 has been documented to be ubiquitously expressed in the human colon, with increased activity in the colonic mucosa of patients with ulcerative colitis, a main form of inflammatory bowel disease. Other experiments have also suggested that expression of ADAM17 may be inhibited by ethanol.
Male and female animals underwent a standardized phenotypic screen to determine the effects of deletion. Twenty eight tests were carried out on mutant mice and two significant abnormalities were observed. Few homozygousmutant embryos were identified during gestation. The remaining tests were carried out on heterozygous mutant adult mice; an increased bone mineral content was observed in these animals using Micro-CT.
^Peiretti F, Deprez-Beauclair P, Bonardo B, Aubert H, Juhan-Vague I, Nalbone G (May 2003). "Identification of SAP97 as an intracellular binding partner of TACE". Journal of Cell Science116 (Pt 10): 1949–57. doi:10.1242/jcs.00415. PMID12668732.
^Poghosyan Z, Robbins SM, Houslay MD, Webster A, Murphy G, Edwards DR (Feb 2002). "Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases". The Journal of Biological Chemistry277 (7): 4999–5007. doi:10.1074/jbc.M107430200. PMID11741929.
^Taïeb J, Delarche C, Ethuin F, Selloum S, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S (Dec 2002). "Ethanol-induced inhibition of cytokine release and protein degranulation in human neutrophils". Journal of Leukocyte Biology72 (6): 1142–7. PMID12488495.
Bonaldo MF, Lennon G, Soares MB (Sep 1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Research6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID8889548.
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (Feb 1997). "A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells". Nature385 (6618): 729–33. doi:10.1038/385729a0. PMID9034190.
Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD (Feb 1997). "Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha". Nature385 (6618): 733–6. doi:10.1038/385733a0. PMID9034191.
Patel IR, Attur MG, Patel RN, Stuchin SA, Abagyan RA, Abramson SB, Amin AR (May 1998). "TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha". Journal of Immunology160 (9): 4570–9. PMID9574564.
Hirohata S, Seldin MF, Apte SS (Nov 1998). "Chromosomal assignment of two ADAM genes, TACE (ADAM17) and MLTNB (ADAM19), to human chromosomes 2 and 5, respectively, and of Mltnb to mouse chromosome 11". Genomics54 (1): 178–9. doi:10.1006/geno.1998.5544. PMID9806848.
Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlöndorff J, Tempst P, Choi Y, Blobel CP (May 1999). "Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival". The Journal of Biological Chemistry274 (19): 13613–8. doi:10.1074/jbc.274.19.13613. PMID10224132.
Cerretti DP, Poindexter K, Castner BJ, Means G, Copeland NG, Gilbert DJ, Jenkins NA, Black RA, Nelson N (Aug 1999). "Characterization of the cDNA and gene for mouse tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and its location to mouse chromosome 12 and human chromosome 2p25". Cytokine11 (8): 541–51. doi:10.1006/cyto.1998.0466. PMID10433800.
Kärkkäinen I, Rybnikova E, Pelto-Huikko M, Huovila AP (Jun 2000). "Metalloprotease-disintegrin (ADAM) genes are widely and differentially expressed in the adult CNS". Molecular and Cellular Neurosciences15 (6): 547–60. doi:10.1006/mcne.2000.0848. PMID10860581.
Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israël A (Feb 2000). "A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE". Molecular Cell5 (2): 207–16. doi:10.1016/S1097-2765(00)80417-7. PMID10882063.
Lee MH, Verma V, Maskos K, Becherer JD, Knäuper V, Dodds P, Amour A, Murphy G (Jun 2002). "The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3". FEBS Letters520 (1-3): 102–6. doi:10.1016/S0014-5793(02)02776-X. PMID12044879.
Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Moyer M, Patel I, Waitt GM, Becherer JD, Moss ML, Milla ME (Jul 2002). "The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity". Biochemistry41 (30): 9462–9. doi:10.1021/bi0260132. PMID12135369.
Gómez-Gaviro MV, González-Alvaro I, Domínguez-Jiménez C, Peschon J, Black RA, Sánchez-Madrid F, Díaz-González F (Oct 2002). "Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs". The Journal of Biological Chemistry277 (41): 38212–21. doi:10.1074/jbc.M205142200. PMID12147693.
Zheng Y, Schlondorff J, Blobel CP (Nov 2002). "Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1". The Journal of Biological Chemistry277 (45): 42463–70. doi:10.1074/jbc.M207459200. PMID12207026.